FDA’s next medical-device fee deal is in public comment until Friday
A five-year deal that helps pay for FDA review of medical devices reached its public-meeting day today. The written comment window is short: the Federal Register notice says comments are due 30 days after July 8, which puts the deadline on August 7.
What happened today
The Food and Drug Administration held a hybrid public meeting today on the next Medical Device User Fee Amendments package, usually shortened to MDUFA. That program lets the FDA collect fees from device companies and use the money to review device applications. The current law ends on September 30, 2027; the new package would cover fiscal years 2028 through 2032.
This sounds procedural, but it controls a part of the health system people touch every day: glucose monitors, implants, home tests, imaging tools, hospital equipment, and software that can become a regulated medical device. The fee deal does not decide whether a product is safe on its own. It sets review goals, staffing assumptions, meeting paths, and the basic service contract between industry money and public oversight.
The useful part: the docket is still open
The meeting itself ran from 10 a.m. to 3 p.m. Eastern. The written docket matters more for most readers, because it is the part still available after the webcast ends. The Federal Register notice says electronic comments go through Regulations.gov and must include docket number FDA-2026-N-6655. It also warns that electronic comments, including attachments, will be posted unchanged, so people should not put private medical or business information in the body of a public filing.
Known fact: the FDA page links the August 5 meeting, the Federal Register notice, a draft commitment letter, and a factsheet. Inference: if you work in health software, diagnostics, hospital operations, patient advocacy, or device investment, this is one of the better moments to read the draft before the rules harden into legislative text.
Why a fee agreement deserves public attention
User-fee programs create a tension that can’t be wished away. Faster reviews can help patients get useful devices sooner, and predictable timelines help smaller companies raise money. But the same structure also means part of the review system depends on fees from the companies asking for review. The public meeting requirement exists because Congress wanted a view outside FDA and industry before reauthorization moves forward.
The right question is not “fees or no fees.” Congress has used this model for decades. The question is whether the next letter buys speed without weakening review quality, whether FDA staffing promises match the work coming in, and whether newer device types, especially software-heavy products, get enough attention in the review process. Those are public questions, not only trade-association questions.
What to open first
Start with the FDA MDUFA VI page. It is the clean index: meeting page, Federal Register notice, draft letter, and factsheet in one place. Then open the Federal Register notice for the actual comment instructions and deadline language. If you submit a comment, keep it short, specific, and free of private information.